Seer, Inc. (California)

As of August 20, 2025, Seer, Inc. shows a mildly bearish trend despite outperforming the S&P 500 over the past year, with a return of 24.29% compared to the S&P's 17.14%, but significantly underperformed over three years with a return of -74.03% versus the S&P's 70.41%.

Seer, Inc. is currently considered risky and overvalued due to negative financial metrics, despite a recent 24.29% return outperforming the S&P 500, while its long-term outlook is troubling with a 3-year return of -74.03%.

As of August 12, 2021, Seer, Inc. is considered overvalued and rated as "risky" due to poor financial metrics, including a Price to Book Value of 0.43, an EV to EBIT of 1.08, a -27.61% ROE, and underperformance against the S&P 500 with a year-to-date return of -14.72%.

As of June 17, 2025, Seer, Inc. is in a mildly bearish trend due to daily moving averages, despite some bullish signals from weekly indicators, suggesting caution in the current market environment.

Seer, Inc. (California) is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $4 million and a net loss of $20 million as of March 2025, with a market cap of $115.34 million. Key metrics include a negative P/E ratio, a debt-equity ratio of -0.76, and a return on equity of -27.61%.

As of Jun 18, Seer, Inc. (California) has a market capitalization of 115.34 million and reported net sales of 15.26 million, with a net profit loss of 85.87 million. Shareholder's funds are 327.57 million, and total assets are 366.60 million.